Citations

Mayo Clinic

Showing 10 of 108602 citations.

Are we improving? Temporal trends in outcomes for mechanical thrombectomy for stroke: A systematic review and meta-analysis of randomized trials
Kobeissi, Hassan , Ghozy, Sherief , Bilgin, Cem , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Ghozy, Sherief , Kobeissi, Hassan , Bilgin, Cem

Interventional Neuroradiology | February 22, 2023 | Volume: 32 | Issue: 3 | Pages: 685-690

10.1177/15910199231158938 | PMID 36924270 Get It

Background In 2015, mechanical thrombectomy (MT) was deemed the standard of care for acute ischemic stroke (AIS) in the anterior circulation due to large vessel occlusion (LVO). To determine if outcomes in patients treated with MT have changed, we conducted a systematic review and meta-analysis of published randomized controlled trials (RCTs). Methods A systematic literature review of the English language literature was conducted using PubMed. We included RCTs that focused on patients with AIS treated with MT. The primary outcome of interest was good functional outcome defined as modified Rankin Scale (mRS) 0–2 at 90 days. Safety outcomes included rates of symptomatic intracranial hemorrhage (sICH) and mortality at 90 days. Using Joinpoint Regression Analysis Program, we calculated the average annual percent change (AAPC) for the outcomes of interest. Results We included 23 RCTs with 5784 patients. The years of mid-enrollment among the included RCTs ranged from 2012–2020. There was an AAPC of +3.82% between 2012 and 2020 (95% CI 0.4 to 7.3; P -value = 0.033) in rates of good functional outcome. There was an AAPC of +6.98% between 2012 and 2020 (95% CI 0.5 to 13.9; P -value = 0.039) in rates of sICH. There was an AAPC of −0.49% between 2012 and 2020 (95% CI −4.4 to 3.5; P -value = 0.77) in rates of mortality. Conclusion Between 2012 and 2020, rates of good functional outcome and sICH increased, while rates of mortality remained consistent in RCTs investigating MT for AIS. Multiple factors likely influenced our results, including increased use of MT and utilization of adjunctive therapies alongside MT.
DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
Huntington, Scott F. , Ding, Wei , Koehler, Amber B. , Brander, Danielle M. , Leis, José F., Iqbal, Madiha , Kearney, Albert S., McKinlay, Timothy P., Gui, Min, Mato, Anthony R. , Ding, Wei , Rosenthal, Allison , Iqbal, Madiha , Schuster, Stephen J. , Tun, Han W. , Moustafa, Muhamad Alhaj , He, Wei , McKinlay, Tim, Gui, Min

American Journal of Hematology | February 22, 2023 | Volume: 98 | Issue: 5 | Pages: 739-749

10.1002/ajh.26888 | PMID 36810799 Get It

Abstract Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase inhibitors (BTKi) with inhibitors of mammalian target of rapamycin (mTOR) and immunomodulatory agents (IMiD). We conducted a phase 1, open‐label study at five centers in USA to evaluate the safety of triplet BTKi/mTOR/IMiD therapy. Eligible patients were adults aged 18 years or older with relapsed/refractory CLL, B cell NHL, or Hodgkin lymphoma. Our dose escalation study used an accelerated titration design and moved sequentially from single agent BTKi (DTRMWXHS‐12), doublet (DTRMWXHS‐12 + everolimus), and then to triplet therapy (DTRMWXHS‐12 + everolimus + pomalidomide). All drugs were dosed once daily on days 1–21 of each 28‐day cycle. The primary goal was to establish the recommended phase 2 dose of the triplet combination. Between September 27, 2016, and July 24, 2019, a total of 32 patients with a median age of 70 years (range 46 to 94 years) were enrolled. No MTD was identified for monotherapy and the doublet combination. The MTD for the triplet combination was determined to be DTRMWXHS‐12 200 mg + everolimus 5 mg + pomalidomide 2 mg. Responses across all studied cohorts were seen in 13 of 32 (41.9%). Combining DTRMWXHS‐12 with everolimus and pomalidomide is tolerable and shows clinical activity. Additional trials could confirm benefit of this all‐oral combination therapy for relapsed/refractory lymphomas.
Instructional Strategies and Student eTextbook Reading
Russell, J. M. , Smith, Anna Marie , George, Salim , Damman, Bryce , Damman, Bryce

LAK23: 13th International Learning Analytics and Knowledge Conference | February 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: 613-618

10.1145/3576050.3576086 Get It

In Response: Women Leadership in Liver Transplantation
Pai, Sher‐Lu , Selzner, Nazia

Transplantation | February 21, 2023 | Volume: 107 | Issue: 3 | Pages: e85-e85

10.1097/tp.0000000000004495 | PMID 36808853 Get It

An Uncommon Cause of Severe Polyradiculopathy
Grill, Marie , Gupta, Simran

Annals of Internal Medicine: Clinical Cases | February 21, 2023 | Volume: 2 | Issue: 2 | Pages: No page available

10.7326/aimcc.2022.0369 Get It

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Kase, Adam M. , Azzouqa, Abdel‐Ghani, Kochuveettil, Swapna, Colón‐Otero, Gerardo

Cancer Medicine | February 21, 2023 | Volume: 12 | Issue: 8 | Pages: 9434-9438

10.1002/cam4.5705 | PMID 36806695 Get It

AbstractBackgroundThe objective of this study was to evaluate the efficacy of gemcitabine plus nab‐paclitaxel in patients with recurrent ovarian cancer.MethodsWe performed a single institution retrospective review of patients with recurrent ovarian cancer who were treated with gemcitabine plus nab‐paclitaxel from 2012 to 2018 at the Mayo Clinic in Florida.ResultsTwenty patients were identified and the median PFS for patients treated with gemcitabine plus nab‐paclitaxel was 9 months (95% CI, 5.7–20.7). Overall, 17 of the 20 patients (85%) achieved a clinical benefit (complete response 5%, partial response 55%, or stable disease at 3 months 25%). For platinum‐sensitive disease and platinum‐resistant disease, the median OS were 38.7 months (95% CI, 5.8–63.1) and 31.2 months (95% CI, 12.8–51.8), respectively (p = 0.4306).ConclusionThis well‐tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.
Survival of anterior cruciate ligament reconstructions in active‐duty military populations
Anderson, Ashley B. , Dekker, Travis J. , Pav, Veronika , Mauntel, Timothy C. , Provencher, Matthew T. , Tokish, John M. , Musahl, Volker , Sansone, Michael , Dickens, Jonathan F. , Dickens, Jonathan F , Extremity War Injury Symposium Working Group , Provencher, Matthew T. , Sansone, Michael, Karlsson, Jón

Knee Surgery, Sports Traumatology, Arthroscopy | February 21, 2023 | Volume: 31 | Issue: 8 | Pages: 3196-3203

10.1007/s00167-023-07335-w | PMID 36809509 Get It

AbstractPurposeAnterior cruciate ligament tears and anterior cruciate ligament reconstruction (ACLR) are common in young athletes. The modifiable and non‐modifiable factors contributing to ACLR failure and reoperation are incompletely understood. The purpose of this study was to determine ACLR failure rates in a physically high‐demand population and identify the patient‐specific risk factors, including prolonged time between diagnosis and surgical correction, that portend failure.MethodsA consecutive series of military service members with ACLR with and without concomitant procedures (meniscus [M] and/or cartilage [C]) done at military facilities between 2008 and 2011 was completed via the Military Health System Data Repository. This was a consecutive series of patients without a history of knee surgery for two years prior to the primary ACLR. Kaplan–Meier survival curves were estimated and evaluated with Wilcoxon test. Cox proportional hazard models calculated hazard ratios (HR) with 95% confidence intervals (95% CI) to identify demographic and surgical factors that influenced ACLR failure.ResultsOf the 2735 primary ACLRs included in the study, 484/2,735 (18%) experienced ACLR failure within four years, including (261/2,735) (10%) undergoing revision ACLR and (224/2,735) (8%) due to medical separation. The factors that increased failure include Army Service (HR 2.19, 95% CI 1.67, 2.87), > 180 days from injury to ACLR (HR 1.550, 95% CI 1.157, 2.076), tobacco use (HR 1.429 95% CI 1.174, 1.738), and younger patient age (HR 1.024, 95% CI 1.004, 1.044).ConclusionThe overall clinical failure rate of service members with ACLR is 17.7% with minimum four‐year follow‐up, where more patients are likely to fail due to revision surgery than medical separation. The cumulative probability of survival at 4 years was 78.5%. Smoking cessation and treating ACLR patients promptly are modifiable risk factors impacting either graft failure or medical separation.Level of evidenceLevel III.
Out of View: A Large Esophageal Ulcer With Fistula to the Spine
Koop, Andree , Villalba, Michael , Hashash, Jana G.

ACG Case Reports Journal | February 21, 2023 | Volume: 10 | Issue: 2 | Pages: e00883

10.14309/crj.0000000000000883 | PMID 36846358 Get It

Medical Parasitology Taxonomy Update, June 2020–June 2022
Mathison, Blaine A. , Bradbury, Richard S. , Pritt, Bobbi S. , Pritt, Bobbi S , Mathison, Blaine A

Journal of Clinical Microbiology | February 21, 2023 | Volume: 61 | Issue: 5 | Pages: No page available

10.1128/jcm.00286-22 Get It

The taxonomy of medically important parasites continues to evolve. This minireview provides an update of additions and updates in the field of human parasitology from June 2020 through June 2022. A list of previously reported nomenclatural changes that have not been broadly adapted by the medical community is also included.
Undiagnosed obstructive sleep apnea increases risk of hospitalization among a racially diverse group of older adults with comorbid cardiovascular disease
Kirk, Jennifer , Somers, Virend K., Albrecht, Jennifer S. , Wickwire, Emerson M. , Somers, Virend K. , Johnson, Dayna A.

Journal of Clinical Sleep Medicine | February 21, 2023 | Volume: 19 | Issue: 7 | Pages: 1175-1181

10.5664/jcsm.10526 | PMID 36803353 Get It